New US Biotech Co To Fight Against Heart Disease
A new biotechnology company, called CardioGene Therapeutics, dedicatedexclusively to cardiovascular disease research and product development using state-of-the-art gene therapy technology has been formed, and will be based in Princeton, New Jersey.
CardioGene intends to develop products dedicated to treating restenosis, angiogenesis, atherosclerosis, arrhythmias and heart failure. Through licensing agreements with Vical and the Universities of Michigan and Chicago, the company has assembled a technology platform consisting of one US patent and 11 patent applications encompassing gene, vector and device technologies.
Scientific Team Former president of Theragen, Martin Cleary, will be president and chief executive, while the group has three scientific founders: Gary and Elizabeth Nabel from the University of Michigan and Jeffrey Leiden from the University of Chicago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze